Sujun Han, Feiya Yang, Yong Zhang, Xiongjun Ye, Hongzhe Shi, Bolin Jia, Xingang Bi, Wasilijiang Wahafu, Hongsong Bai, Linjun Hu, Xin Wang, Nianzeng Xing. "Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4588